RT Journal Article
SR Electronic
T1 Integrative analysis of viral entry networks and clinical outcomes identifies a protective role for spironolactone in severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.02.22277181
DO 10.1101/2022.07.02.22277181
A1 Cousins, Henry
A1 Kline, Adrienne Sarah
A1 Wang, Chengkun
A1 Qu, Yuanhao
A1 Wang, Mengdi
A1 Altman, Russ
A1 Luo, Yuan
A1 Cong, Le
YR 2022
UL http://medrxiv.org/content/early/2022/07/06/2022.07.02.22277181.abstract
AB Treatment strategies that target host entry factors have proven an effective means of impeding viral entry in HIV and may be more robust to viral evolution than drugs targeting viral proteins directly. High-throughput functional screens provide an unbiased means of identifying genes that influence the infection of host cells, while retrospective cohort analysis can measure the real-world, clinical potential of repurposing existing therapeutics as antiviral treatments. Here, we combine these two powerful methods to identify drugs that alter the clinical course of COVID-19 by targeting host entry factors. We demonstrate that integrative analysis of genome-wide CRISPR screening datasets enables network-based prioritization of drugs modulating viral entry, and we identify three common medications (spironolactone, quetiapine, and carvedilol) based on their network proximity to putative host factors. To understand the drugs’ real-world impact, we perform a propensity-score-matched, retrospective cohort study of 64,349 COVID-19 patients and show that spironolactone use is associated with improved clinical prognosis, measured by both ICU admission and mechanical ventilation rates. Finally, we show that spironolactone exerts a dose-dependent inhibitory effect on viral entry in a human lung epithelial cell line. Our results suggest that spironolactone may improve clinical outcomes in COVID-19 through tissue-dependent inhibition of viral entry. Our work further provides a potential approach to integrate functional genomics with real-world evidence for drug repurposing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institutes of Health [GM007365 to H.C., GM102365 to R.A., LM013337 to Y.L., and HG011316 to L.C.], by the Donald and Delia Baxter Foundation [to L.C.], by the National Science Foundation [1953686 to M.W. and 1953415 to L.C.], and by the Knight-Hennessy Scholarships [to H.C.]. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Northwestern University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.